Trials / Withdrawn
WithdrawnNCT00564161
VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 25 Weeks – 40 Weeks
- Healthy volunteers
- Not accepted
Summary
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.
Conditions
Timeline
- Start date
- 2008-01-01
- Completion
- 2009-01-01
- First posted
- 2007-11-27
- Last updated
- 2016-09-02
Source: ClinicalTrials.gov record NCT00564161. Inclusion in this directory is not an endorsement.